Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Safety and Efficacy of Celecoxib Versus Diclofenac in the Treatment of Ankylosing Spondylitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00648141
Recruitment Status : Completed
First Posted : April 1, 2008
Last Update Posted : April 10, 2008
Information provided by:

Brief Summary:
To compare the safety and efficacy of once-daily and twice-daily celecoxib versus diclofenac for the treatment of ankylosing spondylitis

Condition or disease Intervention/treatment Phase
Spondylitis, Ankylosing Drug: Celecoxib Drug: Diclofenac Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 458 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A 12-Week Symptomatic Effect Evaluation to Compare Celecoxib 200 mg QD, Celecoxib 200 mg BID and Diclofenac 75 mg SR BID in Patients With Ankylosing Spondylitis
Study Start Date : January 2003
Actual Study Completion Date : January 2005

Arm Intervention/treatment
Experimental: A Drug: Celecoxib
200 mg oral capsule once daily for 12 weeks

Experimental: B Drug: Celecoxib
200 mg oral capsule twice daily for 12 weeks

Active Comparator: C Drug: Diclofenac
75 mg oral capsule twice daily for 12 weeks

Primary Outcome Measures :
  1. Change from baseline in global pain intensity as assessed by visual analog scale (VAS) [ Time Frame: Week 12 ]
  2. Responder rates, defined as 50% improvement in VAS from baseline [ Time Frame: Week 12 ]

Secondary Outcome Measures :
  1. Patient's and physician's global assessment of disease activity [ Time Frame: Weeks 1, 2, 6, and 12 ]
  2. Spinal pain [ Time Frame: Weeks 1, 2, 6, and 12 ]
  3. Short Form-12 [ Time Frame: Weeks 1, 2, 6, and 12 ]
  4. Adverse events [ Time Frame: Week 12 ]
  5. Physical evaluation [ Time Frame: Week 12 ]
  6. Laboratory tests [ Time Frame: Week 12 ]
  7. Nocturnal pain [ Time Frame: Weeks 1, 2, 6, and 12 ]
  8. Composite Bath Ankylosing Spondylitis Disease Activity Index [ Time Frame: Weeks 1, 2, 6, and 12 ]
  9. Bath Ankylosing Spondylitis Metrology Index [ Time Frame: Weeks 1, 2, 6, and 12 ]
  10. Change from baseline in C-reactive protein measurement [ Time Frame: Week 12 ]
  11. Responder rates, defined as 50% improvement in VAS from baseline [ Time Frame: Weeks 1, 2, and 6 ]
  12. Mobility parameters [ Time Frame: Weeks 1, 2, 6, and 12 ]
  13. Change from baseline in Assessments in Ankylosing Spondylitis 20 score [ Time Frame: Weeks 1, 2, 6, and 12 ]
  14. Change from baseline in global pain intensity [ Time Frame: Weeks 1, 2, and 6 ]
  15. Bath Ankylosing Spondylitis Functional Index [ Time Frame: Weeks 1, 2, 6, and 12 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of ankylosing spondylitis defined according to modified New York criteria, and with axial involvement
  • Requiring daily treatment with nonsteroidal anti-inflammatory drugs during the previous 30 days

Exclusion Criteria:

  • Patients with inflammatory enterophathy, and with extra-articular manifestations
  • Patients with known vertebral compression
  • Received corticosteroids 6 weeks prior to the baseline visit; patients on stable dose of prednisolone equivalents ≤ 10 mg/ day for at least 14 days before randomization were permitted

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00648141

Layout table for location information
Pfizer Investigational Site
Aachen, Germany, 52064
Pfizer Investigational Site
Bad Aibling, Germany, 83043
Pfizer Investigational Site
Bad Iburg, Germany, 49186
Pfizer Investigational Site
Bad Muender, Germany, 31848
Pfizer Investigational Site
Berlin, Germany, 10559
Pfizer Investigational Site
Berlin, Germany, 10777
Pfizer Investigational Site
Berlin, Germany, 12200
Pfizer Investigational Site
Berlin, Germany, 12247
Pfizer Investigational Site
Berlin, Germany, 13125
Pfizer Investigational Site
Berlin, Germany, 14059
Pfizer Investigational Site
Berlin, Germany, D-10098
Pfizer Investigational Site
Bonn, Germany, 53179
Pfizer Investigational Site
Celle / OT Klein Hehlen, Germany, 29223
Pfizer Investigational Site
Chemnitz, Germany, 09130
Pfizer Investigational Site
Darmstadt, Germany, 64295
Pfizer Investigational Site
Dresden, Germany
Pfizer Investigational Site
Duesseldorf, Germany, 40211
Pfizer Investigational Site
Elmshorn, Germany, 25335
Pfizer Investigational Site
Erlangen, Germany, 91056
Pfizer Investigational Site
Halle, Germany, 06128
Pfizer Investigational Site
Hannover, Germany, 30161
Pfizer Investigational Site
Heidelberg, Germany, 69120
Pfizer Investigational Site
Hildesheim, Germany, 31134
Pfizer Investigational Site
Hofheim, Germany, 65719
Pfizer Investigational Site
Hoyerswerda, Germany, 02977
Pfizer Investigational Site
Koeln, Germany, 51107
Pfizer Investigational Site
Leipzig, Germany, 04107
Pfizer Investigational Site
Leverkusen, Germany, 51373
Pfizer Investigational Site
Magdeburg, Germany, 39104
Pfizer Investigational Site
Mannheim, Germany, 68165
Pfizer Investigational Site
Muenchen, Germany, 80336
Pfizer Investigational Site
Neubrandenburg, Germany, 17033
Pfizer Investigational Site
Oldenburg, Germany, 26121
Pfizer Investigational Site
Osnabrueck, Germany, 49074
Pfizer Investigational Site
Pirna, Germany, 01796
Pfizer Investigational Site
Ratingen, Germany, D40882
Pfizer Investigational Site
Regensburg, Germany
Pfizer Investigational Site
Remscheid, Germany, 42897
Pfizer Investigational Site
Rheine, Germany, 48431
Pfizer Investigational Site
Rostock, Germany, 18059
Pfizer Investigational Site
Saarbruecken, Germany, 66111
Pfizer Investigational Site
Seesen, Germany, 38723
Pfizer Investigational Site
Surwold, Germany, 26903
Pfizer Investigational Site
Tuebingen, Germany, 72076
Pfizer Investigational Site
Villingen-Schwenningen, Germany, 78054
Pfizer Investigational Site
Weener, Germany, 26826
Pfizer Investigational Site
Winsen/Luhe, Germany, 21423
Sponsors and Collaborators
Layout table for investigator information
Study Director: Pfizer Call Center Pfizer
Additional Information:
Layout table for additonal information
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc Identifier: NCT00648141    
Other Study ID Numbers: COXA-0508-243
First Posted: April 1, 2008    Key Record Dates
Last Update Posted: April 10, 2008
Last Verified: March 2008
Additional relevant MeSH terms:
Layout table for MeSH terms
Spondylitis, Ankylosing
Bone Diseases, Infectious
Bone Diseases
Musculoskeletal Diseases
Spinal Diseases
Joint Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action